Abstract
The cell cycle is the series of events necessary for the division and duplication of a cell. The dysregulation of the cell cycle can promote the development of cancer. A group of proteins, cyclin-dependent kinases (CDKs), that control the cell cycle, provide new targets for treating cancer. As a result, cyclin-dependent kinase inhibitors (CDKIs) represent a novel class of chemotherapeutic agents. Of these, flavopiridol, a semisynthetic flavonoidal alkaloid, emerged as the first CDKI to enter clinical trials. Preclinical data indicate that flavopiridol could block the proliferation of neoplastic cells and induce programmed cell death as a single agent. Furthermore, recent emerging data revealed that flavopiridol can potentiate, generally in a dose- and sequence-dependent manner, the anti-tumor effects of many established chemotherapeutic agents. This review is primarily focused on the role of flavopiridol in combination with various therapeutic agents that are in or near clinical development.
Keywords: Anticancer, cancer, CDKIs, combination therapy, flavopiridol, flavonoid, Cyclin-Dependent Kinase Inhibitor, Combination Chemotherapy, Chemotherapeutic agents, Anti-tumor effects, Therapeutic agents, Mammalian enzyme systems, Dysoxylum binectariferum, Vascular endothelial growth factor (VEGF), Inhibit angiogenesis, Structure-activity relationships, Dose-limiting toxicities (DLT), Rohitukine, Oxoflavopiridols, P-TEFb, Adenine binding pocket, Pan-CDK inhibitors, Antiproliferative effect, Antiangiogenic effect, Flavopiridol's activation, Radiation-induced cytotoxicity, Docetaxel (FD), Histone Deacetylase Inhibitors (HDACIs), Cancer cell line OCA-I, Proteasome Inhibitors, Monoclonal Antibodies, Breast cancer mortality, T-cell leukemia, Gemcitabine, non-hematological malignancies, Antineoplastic agents, Gelatin microspheres (GMSs), Hyponatremia, thrombocytopenia, Neutropenia, Mitoxantrone, Humanized anti-Tac antibody, Histone deacetylase inhibitors, Hypoxia-inducible factor
Mini-Reviews in Medicinal Chemistry
Title: Flavopiridol, the First Cyclin-Dependent Kinase Inhibitor: Recent Advances in Combination Chemotherapy
Volume: 10 Issue: 11
Author(s): L.-M. Wang and D.-M. Ren
Affiliation:
Keywords: Anticancer, cancer, CDKIs, combination therapy, flavopiridol, flavonoid, Cyclin-Dependent Kinase Inhibitor, Combination Chemotherapy, Chemotherapeutic agents, Anti-tumor effects, Therapeutic agents, Mammalian enzyme systems, Dysoxylum binectariferum, Vascular endothelial growth factor (VEGF), Inhibit angiogenesis, Structure-activity relationships, Dose-limiting toxicities (DLT), Rohitukine, Oxoflavopiridols, P-TEFb, Adenine binding pocket, Pan-CDK inhibitors, Antiproliferative effect, Antiangiogenic effect, Flavopiridol's activation, Radiation-induced cytotoxicity, Docetaxel (FD), Histone Deacetylase Inhibitors (HDACIs), Cancer cell line OCA-I, Proteasome Inhibitors, Monoclonal Antibodies, Breast cancer mortality, T-cell leukemia, Gemcitabine, non-hematological malignancies, Antineoplastic agents, Gelatin microspheres (GMSs), Hyponatremia, thrombocytopenia, Neutropenia, Mitoxantrone, Humanized anti-Tac antibody, Histone deacetylase inhibitors, Hypoxia-inducible factor
Abstract: The cell cycle is the series of events necessary for the division and duplication of a cell. The dysregulation of the cell cycle can promote the development of cancer. A group of proteins, cyclin-dependent kinases (CDKs), that control the cell cycle, provide new targets for treating cancer. As a result, cyclin-dependent kinase inhibitors (CDKIs) represent a novel class of chemotherapeutic agents. Of these, flavopiridol, a semisynthetic flavonoidal alkaloid, emerged as the first CDKI to enter clinical trials. Preclinical data indicate that flavopiridol could block the proliferation of neoplastic cells and induce programmed cell death as a single agent. Furthermore, recent emerging data revealed that flavopiridol can potentiate, generally in a dose- and sequence-dependent manner, the anti-tumor effects of many established chemotherapeutic agents. This review is primarily focused on the role of flavopiridol in combination with various therapeutic agents that are in or near clinical development.
Export Options
About this article
Cite this article as:
Wang L.-M. and Ren D.-M., Flavopiridol, the First Cyclin-Dependent Kinase Inhibitor: Recent Advances in Combination Chemotherapy, Mini-Reviews in Medicinal Chemistry 2010; 10 (11) . https://dx.doi.org/10.2174/1389557511009011058
DOI https://dx.doi.org/10.2174/1389557511009011058 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Histone Deacetylase Inhibitors as Potent Modulators of Cellular Contacts
Current Drug Targets Graphene Oxide: A Carrier for Pharmaceuticals and a Scaffold for Cell Interactions
Current Topics in Medicinal Chemistry Antioxidant Supplements, Genetics and Chemotherapy Outcomes
Current Cancer Therapy Reviews Low Doses Naltrexone: The Potential Benefit Effects for its Use in Patients with Cancer
Current Drug Research Reviews HSP60 as a Drug Target
Current Pharmaceutical Design Novel Anti-Angiogenic Compounds for Application in Tumor Therapy – COP9 Signalosome-Associated Kinases as Possible Targets
Mini-Reviews in Medicinal Chemistry Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target
Current Medicinal Chemistry Advanced Platelet-Rich Fibrin Extract Treatment Promotes the Proliferation and Differentiation of Human Adipose-Derived Mesenchymal Stem Cells through Activation of Tryptophan Metabolism
Current Stem Cell Research & Therapy Radiosensitization of Prostate Cancer by Soy Isoflavones
Current Cancer Drug Targets Possible Consequences of Blocking Transient Receptor Potential Vanilloid 1
Current Pharmaceutical Biotechnology Duration of Dual Antiplatelet Therapy After Coronary Stenting
Current Pharmaceutical Design Recent Trends of Chalcones Potentialities as Antiproliferative and Antiresistance Agents
Anti-Cancer Agents in Medicinal Chemistry Withdrawal Notice: The Recent Advancement in the Field of Super Paramagnetic Iron Oxide Nanoparticles (SPIONs) for Aiming Breast Cancer
Current Drug Metabolism The Role of TRP Channels in Allergic Inflammation and its Clinical Relevance
Current Medicinal Chemistry Cancer Prevention with Promising Natural Products: Mechanisms of Action and Molecular Targets
Anti-Cancer Agents in Medicinal Chemistry DNA Methylation and Bladder Cancer: Where Genotype does not Predict Phenotype
Current Genomics Tumor-Targeting Peptides and Small Molecules as Anti-Cancer Agents to Overcome Drug Resistance
Current Medicinal Chemistry Patented Biomarkers of Peripheral Blood for the Early Detection of Cancer
Recent Patents on Biomarkers Specialisation of the Tropomyosin Composition of Actin Filaments Provides New Potential Targets for Chemotherapy
Current Cancer Drug Targets Radiolabelled Probes Targeting Tumor Hypoxia for Personalized Medicine
Current Pharmaceutical Design